Abstract:Highlights This is the first randomized, double‐blind, controlled clinical trial collecting data on the efficacy and safety of bexagliflozin compared to that of dapagliflozin in Chinese patients with type 2 diabetes mellitus. Bexagliflozin provides identical efficacy in improving key efficacy parameters including glycated hemoglobin, fasting plasma glucose, 2‐h postprandial blood glucose, and clinical response without an increase in adverse events compared with dapagliflozin. Background Bexagliflozin and dapagliflozin are sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date. Methods This was a multicenter, randomized, double‐blind, active‐controlled trial comparing bexagliflozin to dapagliflozin for the treatment of type 2 diabetes mellitus in adults with disease inadequately controlled by metformin. Subjects (n = 406) were randomized to receive bexagliflozin (20 mg) or dapagliflozin (10 mg) plus metformin. The primary endpoint was noninferiority of bexagliflozin to dapagliflozin for the change in glycated hemoglobin (HbA1c) from baseline to week 24. Secondary endpoints included intergroup differences in fasting plasma glucose (FPG), 2‐h‐postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) from baseline to week 24. The trial also evaluated the safety profiles. Results The model‐adjusted mean change from baseline to week 24 HbA1c was −1.08% for bexagliflozin and −1.10% for dapagliflozin. The intergroup difference of 0.03% (95% confidence interval [CI] −0.14% to 0.19%) was below the prespecified margin of 0.4%, confirming the noninferiority of bexagliflozin. The changes from baseline in FPG, PPG, body weight, and SBP were −1.95 mmol/L, −3.24 mmol/L, −2.52 kg, and −6.4 mm Hg in the bexagliflozin arm and −1.87 mmol/L, −3.07 mmol/L, −2.22 kg, and −6.3 mm Hg in the dapagliflozin arm. Adverse events were experienced in 62.6% and 65.0% and serious adverse events affected 4.4% and 3.5% of subjects in the bexagliflozin and dapagliflozin arm, respectively. Conclusions Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin.

Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.

Efficacy and Safety of Saxagliptin Compared with Acarbose in Chinese Patients with Type 2 Diabetes Mellitus Uncontrolled on Metformin Monotherapy: Results of a Phase IV Open‐label Randomized Controlled Study (the SMART Study)

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

Saxagliptin Add-on Therapy in Chinese Patients with Type 2 Diabetes Inadequately Controlled by Insulin with or Without Metformin: Results from the SUPER Study, a Randomized, Double-Blind, Placebo-Controlled Trial

Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS)

Efficacy and Safety of Combination Therapy with Vildagliptin and Metformin Versus Metformin Uptitration in Chinese Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Randomized, Open-Label, Prospective Study (Vision)

Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.

Author Response for "saxagliptin Combined with Additional Oral Antihyperglycemic Agents in Drug‐naive Diabetic Patients with High Glycosylated Hemoglobin: a 24‐week, Multicenter, Randomized, Open‐label, Active Parallel‐controlled Group Clinical Trial in China (SUCCESS)"

Cost-effectiveness of Saxagliptin Vs Glimepiride As a Second-Line Therapy Added to Metformin in Type 2 Diabetes in China

Efficacy And Safety Of Saxagliptin In Patients With Type 2 Diabetes: A Systematic Review And Meta-Analysis

Cost-Effectiveness Of Saxagliptin Versus Acarbose As Second-Line Therapy In Type 2 Diabetes In China

Comparative Effect Of Saxagliptin And Glimepiride With A Composite Endpoint Of Adequate Glycaemic Control Without Hypoglycaemia And Without Weight Gain In Patients Uncontrolled With Metformin Therapy: Results From The Specify Study, A 48-Week, Multi-Centre, Randomized, Controlled Trial

Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension

[Efficacy and Safety of Alogliptin in Treatment of Type 2 Diabetes Mellitus: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial in Mainland China].

Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Efficacy And Safety Of Linagliptin Monotherapy In Asian Patients With Inadequately Controlled Type2 Diabetes Mellitus: A Multinational, 24-Week, Randomized, Clinical Trial

Efficacy and safety of exenatide in Chinese patients with type 2 diabetes inadequately controlled with metformin or metformin and a sulfonylurea

Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial

The effectiveness and safety of saxagliptin combined with insulin glargine in the treatment of gerontal patients with type 2 diabetes mellitus

Research on clinical application of Saxagliptin in Chinese type 2 diabetic patients